Prograf is an immunosuppressant medication used primarily to prevent organ transplant rejection. Its active ingredient tacrolimus works by inhibiting the activation of t cells that drive immune responses. The drug binds to fk binding protein 12 and forms a complex that blocks calcineurin phosphatase activity downstream of the t cell receptor. This inhibition prevents dephosphorylation of nuclear factor of activated t cells leading to reduced transcription of cytokines such as interleukin 2. By decreasing cytokine production and t cell proliferation the medication lowers the risk of graft rejection and is also employed in treating certain autoimmune conditions. Pharmacokinetically tacrolimus is orally absorbed metabolized by hepatic cytochrome enzymes and eliminated mainly through biliary excretion.

Prograf is the brand name for the immunosuppressant tacrolimus and is used primarily to prevent organ transplant rejection. Its pharmacological action involves inhibiting the activation of t cells by binding to fkbp12 and blocking calcineurin phosphatase activity. This inhibition prevents the transcription of cytokines such as interleukin-2 which are essential for immune response proliferation. By reducing cytokine production Prograf limits the immune system's ability to attack transplanted cells. Clinically it is administered orally and achieves stable blood levels that correlate with therapeutic efficacy and toxicity. The drug is metabolized by the liver enzyme cyp3a4 and its levels are influenced by co-administered medications that affect this pathway. Its therapeutic purpose is to maintain graft survival while minimizing the risk of rejection in patients receiving kidney liver or heart transplants.

Prograf may cause hypertension which should be monitored regularly. It can lead to elevated blood sugar levels in some patients. Kidney function may be affected requiring periodic testing. Tremors or shaking can occur as a neurological side effect. Some users experience headaches that range from mild to moderate. Gastrointestinal disturbances such as nausea are occasionally reported. Swelling of the gums may develop with long term use.

Prograf may affect kidney function, which sometimes requires monitoring. Neurotoxic effects such as headaches, tremors, or confusion can occur in certain patients. Elevated blood pressure, including hypertension, has been noted as a possible side effect. Metabolic disturbances, including increased blood glucose and cholesterol levels, are occasionally reported. Gingival overgrowth, or excessive growth of gum tissue, has been observed in some individuals. The medication can increase susceptibility to infections, particularly those affecting the respiratory tract or skin. A rare but serious risk includes post-transplant lymphoproliferative disorder, which involves abnormal lymphoid cell growth.